Home・Aktien・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Geschlossen

3.82 4.09

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.65

Max

3.85

Schlüsselkennzahlen
By Trading Economics
Einkommen	-42M -78M
EPS	-0.59
Angestellte	106
EBITDA	-42M -77M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+139.95% upside

Dividenden
By Acuity
Nächstes Ergebnis	6. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	20M 351M
Vorheriger Eröffnungskurs	-0.27
Vorheriger Schlusskurs	3.82

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Aug. 2026, 23:56 UTC

News

Wayfair shares rise in after-market hours after Rosenblatt analyst Scott Devitt initiated coverage with a Buy rating and a price target of $125.00.

19. Aug. 2026, 23:56 UTC

Peloton Interactive Inc shares are lower in after-market hours with no specific news to explain the decline. The stock remains below its 20-day moving average.

19. Aug. 2026, 23:56 UTC

Shares of Nova Ltd. rose in after-market trading, despite earlier fluctuations and remaining below its 20-day moving average.

19. Aug. 2026, 23:56 UTC

Certara Inc. shares are lower in after-hours trading, showing slight declines since Wednesday's close while remaining above the 20-day moving average.

19. Aug. 2026, 23:56 UTC

CareDx Inc shares are higher in after-market hours, remaining above their 20-day moving average. No specific news was identified to explain the movement.

19. Aug. 2026, 23:56 UTC

Correlated Moves

Pinnacle West Capital shares are modestly higher in after-market trading, tracking a similar rise in PG&E Corp, indicating potential market correlation.

19. Aug. 2026, 23:56 UTC

Pentair PLC shares are lower in after-market trading, reflecting routine activity and slight declines since Wednesday's close. The price remains near the one-month midpoint.

19. Aug. 2026, 23:56 UTC

Best Buy Co Inc shares are higher in after-market trading, fluctuating slightly while remaining above their 20-day moving average. No specific news was identified.

19. Aug. 2026, 23:56 UTC

Charles River Laboratories shares are higher in after-market trading, reaching a notable increase since Wednesday's close and positioning near the upper end of its one-month range.

19. Aug. 2026, 23:56 UTC

Quest Diagnostics Inc shares are higher in after-market hours, continuing a trend of four consecutive sessions finishing above their 20-day moving average.

19. Aug. 2026, 23:56 UTC

GSI Technology Inc's shares are higher in after-market trading, despite a recent decline and ongoing weakness below the 20-day moving average.

19. Aug. 2026, 23:56 UTC

Invesco DB Agriculture Fund is higher in after-market trading, reflecting a notable upward move since Wednesday's close and trading near its one-month range.

19. Aug. 2026, 23:56 UTC

CF Industries remains roughly flat in after-market hours, trading near the middle of its one-month range and slightly below its 20-day moving average.

19. Aug. 2026, 23:56 UTC

Apollo Global Management shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

19. Aug. 2026, 23:56 UTC

Ares Capital Corp shares are higher in after-market trading, reflecting a generally positive performance backdrop. The stock remains above its 20-day moving average.

19. Aug. 2026, 23:56 UTC

Huntington Bancshares Inc shares are higher in after-market trading, despite no specific news. The stock remains below its 20-day moving average.

19. Aug. 2026, 23:56 UTC

FactSet Research Systems is trading lower in after-market hours, reflecting a decline since Wednesday's close, with no specific news identified for the movement.

19. Aug. 2026, 23:56 UTC

Shoals Technologies Group Inc is trading lower in after-market hours, continuing a downward trend without any specific news to explain the movement.

19. Aug. 2026, 23:56 UTC

News

Social Media

Cogent Communications is facing a class action lawsuit over alleged false statements, contributing to a decline in shares during after-market hours.

19. Aug. 2026, 23:52 UTC

News

Correlated Moves

Cohen & Steers Inc. shares are lower in after-market trading, continuing a trend of five consecutive daily declines. The fund declared a monthly dividend of $0.126 per share.

19. Aug. 2026, 23:52 UTC

Progressive Corp shares are higher in after-market hours, reflecting a modest gain since Wednesday's close. The stock remains above its 20-day moving average.

19. Aug. 2026, 23:51 UTC

Doximity Inc shares are lower in after-market trading, with no specific news identified for the decline. The stock remains above its 20-day moving average.

19. Aug. 2026, 23:51 UTC

Peabody Energy shares are lower in after-market trading, reversing an earlier gain. The stock remains above its 20-day moving average.

19. Aug. 2026, 23:51 UTC

Patria Investments Ltd is trading higher in after-market hours, reaching 2.45% above Wednesday's close and showing strong momentum above its 20-day moving average.

19. Aug. 2026, 23:51 UTC

Workday Inc. shares are higher in after-market trading, continuing a month-long upward trend and remaining above the 20-day moving average.

19. Aug. 2026, 23:51 UTC

Pinterest Inc. shares moved lower in after-market trading, retracing earlier gains and remaining below their 20-day moving average.

19. Aug. 2026, 23:51 UTC

Kilroy Realty Corp shares are lower in after-market trading, continuing a decline since Wednesday's close and positioned below its 20-day moving average.

19. Aug. 2026, 23:51 UTC

Take-Two Interactive shares are higher in after-market hours, recovering from earlier lows. No specific news was identified to explain the price movement.

19. Aug. 2026, 23:51 UTC

News

Biomarin Pharmaceutical Inc shares are lower in after-market hours amid a broader Biotechnology sector decline, despite a recent $275 million acquisition of Alesta Therapeutics.

19. Aug. 2026, 23:51 UTC

Mixed trading in European equities as Eurozone inflation rises to 2.9% and German Bund yields hit a 12-year high amid geopolitical tensions.

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

139.95% Vorteil

12-Monats-Prognose

Durchschnitt 8.83 USD 139.95%

Hoch 11 USD

Tief 5 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Zentalis Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.